Menu Search
Equities

Gland Pharma Ltd

GLAND:NSI

Gland Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,758.80
  • Today's Change-21.20 / -1.19%
  • Shares traded66.34k
  • 1 Year change+0.10%
  • Beta0.6942
Data delayed at least 15 minutes, as of Nov 26 2024 09:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform0
Hold1
Sell4
Strong Sell1

Share price forecast in INR

The 11 analysts offering 12 month price targets for Gland Pharma Ltd have a median target of 1,800.00, with a high estimate of 2,150.00 and a low estimate of 1,214.00. The median estimate represents a 1.12% increase from the last price of 1,780.00.
High20.8%2,150.00
Med1.1%1,800.00
Low-31.8%1,214.00

Earnings history & estimates in INR

On Nov 04, 2024, Gland Pharma Ltd reported 2nd quarter 2025 earnings of 9.93 per share.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate-3.09%
Gland Pharma Ltd reported annual 2024 earnings of 46.89 per share on May 22, 2024.
Average growth rate-7.28%
More ▼

Revenue history & estimates in INR

Gland Pharma Ltd had 2nd quarter 2025 revenues of 14.06bn. This missed the 14.20bn consensus estimate of the 5 analysts following the company. This was 16.31% above the prior year's 2nd quarter results.
Average growth rate+0.87%
Gland Pharma Ltd had revenues for the full year 2024 of 56.65bn. This was 56.63% above the prior year's results.
Average growth rate+21.97%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.